Urine Oxalate and Citrate
EPTIS Ringversuch Nr. 142599 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts142599 https://www.eptis.bam.de/pts142599
| Name des Anbieters | ||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||
| Ansässig in | United Kingdom | |||||||||
| Sprache(n) | ||||||||||
| Anmerkungen | The amounts of oxalate and citrate excreted in urine and their urinary concentrations are important risk factors for the development of kidney stones. Citrate in the urine has long been recognized as an inhibitor of calcium salt crystallization and patients having low citrate levels (hypocitraturia) are at increased risk of kidney stone formation. There are several metabolic disorders associated with low urinary citrate concentrations, any condition which lowers renal tubular pH or intracellular pH, may decrease citrate, e.g. metabolic acidosis, increased acid ingestion, hypokalaemia or hypomagnesaemia. This programme is designed to span both the analytical and clinically relevant range for the diagnosis and management of hyperoxaluria and hypocitraturia. The samples consist of challenging samples at low concentration for citrate as well as a panel of 6 linearly related pools produced from urine donations spiked with oxalate and citrate to span the analytical range. Each sample is distributed on 6 occasions with a minimum of 36 samples distributed over the year. The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Samples cover both analytical and clinically relevant range. - Challenging samples at low citrate concentration. - Linearly related panel assists with your compliance to ISO 15189. For more information: https://www.weqas.com/services/eqa/oxalate-citrate/ or contact@weqas.com | |||||||||
| Klassifizierung | ||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||
| Technische Einzelheiten | ||||||||||
|
||||||||||
| Ringversuchsziele | ||||||||||
| Zielgruppe des Ringversuchs | The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. | |||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | |||||||||
| Weitere Ziele | validation of testing methods | |||||||||
| Teilnehmerzahl | ||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||
| Kosten | ||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 2.5mL.) | |||||||||
| Der Ringversuch wird durchgeführt seit | 2003 | |||||||||
| Kontaktdaten des Anbieters | ||||||||||
| Anbieter | Kontaktperson | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.